Investor Relations

High-growth company with focus on becoming a single-use pure player within all main endoscopy markets.

Latest news

02

Dec. 2025

Introducing Ambu® SureSight™ Mobile video laryngoscope

Following the launch of Ambu® SureSight™ Connect in the U.S. and Great Britain in the first half of 2025, Ambu now expands its video laryngoscope portfolio with Ambu® SureSight™ Mobile – a video laryngoscope with an integrated screen for emergent and unplanned intubations across clinical settings.


Today, Ambu announces the introduction of SureSight Mobile, a portable video laryngoscope solution that expands and brings next-level flexibility to Ambu’s video laryngoscope portfolio.

Designed to be robust, reliable, and durable, the SureSight Mobile features an integrated screen without the need for separate monitors or cables. This all-in-one design enables clinicians to perform emergent and unplanned intubations swiftly and confidently in demanding environments – whether in an ambulance, emergency room, or remote location – making the SureSight Mobile a solution targeted for both pre-hospital and hospital settings. This versatile solution delivers high-quality imaging, empowering clinicians to not only visualize the airway with clarity but also seamlessly document and review the intubation process.

"There is now overwhelming evidence that video laryngoscopy enhances both the safety and efficacy of tracheal intubation compared with direct laryngoscopy. The recently published DAS 2025 Intubation Guidelines recommend that video laryngoscopes be used as the first-line approach for tracheal intubation whenever feasible. The launch of the SureSight Mobile is therefore extremely timely, enabling universal access to video laryngoscopy for all intubations across the hospital environment."

DR. IMRAN AHMAD1
Consultant Anesthetist, Guy's & St Thomas' NHS Foundation Trust, London, UK            


Expanding and leveraging Ambu’s video laryngoscope portfolio
In the U.S. alone, the video laryngoscope market represents roughly DKK 4 billion and is growing 15-20% annually. Today, around 50% of all endotracheal intubations are performed with a video laryngoscope, making it the preferred intubation method across clinical settings. To support this development, Ambu’s expanded video laryngoscope portfolio now offers two SureSight video laryngoscope solutions, including a comprehensive range of 10 blades of different sizes. The breadth of Ambu’s video laryngoscope portfolio ensures that clinicians have a SureSight video laryngoscope for every setting, scenario, and preference – obtaining flexibility, reliability, and confidence across the continuum of care.

Ambu will now engage in a controlled market release phase, collaborating with clinicians at key hospitals across the U.S. and Great Britain, to evaluate the performance of the SureSight Mobile in clinical settings. Subsequently, Ambu will engage in a full launch in 2026.

"With the launch of SureSight Mobile, Ambu is reinforcing our leadership in the Respiratory market. By expanding our portfolio with a mobile video laryngoscope solution, we are addressing the needs clinicians face during unexpected intubation – when time matters most. This innovation reflects our commitment to delivering a comprehensive Respiratory offering of advanced solutions that empower healthcare professionals to make fast, confident decisions and uphold the highest standards of care across clinical settings."

BRITT MEELBY JENSEN
Chief Executive Officer, Ambu

-----------------------------------------------------------------------------------

1 Dr. Ahmad has not been compensated for his quote in this press release.

 

Download the press release here

10

Nov. 2025

Reporting of transactions made by persons discharging managerial responsibilities (no. 5)

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made by Executive Management.

07

Nov. 2025

Reporting of transactions made by persons discharging managerial responsibilities (no. 4)

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made by Executive Management.

 

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Upcoming events

04

Feb. 2026

Earnings release Q1 2025/26

06

May. 2026

Earnings release Q2 2025/26

26

Aug. 2026

Earnings release Q3 2025/26

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up

 

keyboard_arrow_up
close

Health Care Professionals

Text

Text

Text

Text

Text

Text